DelveInsight

View All

DelveInsight’s Launch of Its New & Improved Report Store

DelveInsight is delighted to announce the launch of its report store. Our report store is collection of 3000+ analytical reports from the pharmaceutical as well as biotechnological industry. The store lets you browse through the vast collection of reports, gives you an overview of the different types of reports on o...

Find More

Cervical Cancer: Current Scenario

Cervical cancer is the second most common cause of death in women globally. Increased awareness and early diagnosis has reduced the death toll over the years; but still there is considerable risk that exists. According to the estimated of American Cancer Society, approximately 12,990 new cases of invasive cervical c...

Find More

PI3Kγ- a molecular switch that controls immune suppression

Macrophages play critical role in acute and chronic inflammation and cancer. In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells. Macrophage PI(3)Kinase γ controls a critical switch between immune stimulation and suppression during inflammation and cancer. ...

Find More

Graft vs Host Disease (GVHD): Treatment approaches and Trends

It is a well-known fact that where there is stem cell transplantation, there is Graft vs Host Disease (GVHD). The concept arose 2 decades ago and is not rare- it is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected, and attack t...

Find More

Roche’s drug; Cancer drugs risk; FDA norms; Takeda sets deal

Roche's drug candidate for Multiple Sclerosis touted to be better than Merck’s Rebif The much anticipated multiple sclerosis drug from Roche, ocrelizumab, has overtaken Merck’s Rebif according to the results of Phase III data, and has also shown great stats that could prove that it might have an edge in the hotly co...

Find More

HER2 Expression and its Dynamic Functional States

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2...

Find More

Futuristic Customizable RNA Vaccine

A vaccine is a biological cocktail composed of inactive microorganisms that are either attenuated or dead. It has been found that human immune system maintains a memory of disease causing agents to save the body from the next attack. But vaccines till date are known to treat only specific type of ailments. To ...

Find More

Nav1.7 Blockers- New Genre of Pain Relief Therapy

Voltage-gated sodium channels are membrane proteins, a polypeptide chain of more than 1800 amino acids that conduct sodium ions at high rates. They are embedded in the plasma membrane and are actively present in the nerve and muscle cells used in the rapid electrical signaling. Nav channels are therapeutic targets f...

Find More

Delveinsight
A promising immune-stimulating target

For over 100 years, immunotherapy has played a significant role in the treatment of cancer. Immune stimulatory agents such as Toll-like receptor (TLR) agonists, adoptive T cell and natural killer (NK) cell therapies, cytokine-based therapies etc. have gained approval for treatment of various indications. In 1980s, r...

Find More

Delveinsight
Anticoagulants (VTE & AF) Therapeutics Market

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Antico...

Find More